Sarepta Therapeutics(US:SRPT) Seeking Alpha·2026-01-16 14:25Core Viewpoint - Sarepta Therapeutics (SRPT) has faced significant challenges, particularly with its ELEVIDYS product, which has been described as a regulatory nightmare, impacting the company's stock performance and investor confidence [2]. Group 1: Company Overview - Sarepta Therapeutics specializes in developing innovative therapies for Duchenne Muscular Dystrophy (DMD) and other serious diseases [2]. - The company has been under scrutiny due to regulatory issues surrounding its products, which has led to a decline in stock value [2]. Group 2: Investment Insights - The article suggests that there may be potential for recovery and investment opportunities as the company works through its regulatory challenges [2]. - The author emphasizes a long position in SRPT shares, indicating a belief in the company's future potential despite current setbacks [3].